{"id":"https://openalex.org/W4399323701","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.1091","title":"Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results.","display_name":"Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results.","publication_year":2024,"publication_date":"2024-06-01","ids":{"openalex":"https://openalex.org/W4399323701","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.1091"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2024.42.16_suppl.1091","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.1091","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.1091","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2024.42.16_suppl.1091","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2024.42.16_suppl.1091","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079293274","display_name":"Lasika C. Seneviratne","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lasika C. Seneviratne","raw_affiliation_strings":["Los Angeles Cancer Network, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Los Angeles Cancer Network, Los Angeles, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043562974","display_name":"Kathleen Kiernan Harnden","orcid":"https://orcid.org/0000-0002-8211-708X","observed_orcids":["https://orcid.org/0000-0002-8211-708X"]},"institutions":[{"id":"https://openalex.org/I2800468613","display_name":"Inova Fairfax Hospital","ror":"https://ror.org/0212h5y77","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I116530498","https://openalex.org/I2800468613"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathleen Kiernan Harnden","raw_affiliation_strings":["Inova Schar Cancer Institute, Fairfax, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inova Schar Cancer Institute, Fairfax, VA","institution_ids":["https://openalex.org/I2800468613"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070081606","display_name":"Sibel H. Blau","orcid":"https://orcid.org/0000-0002-5249-1521","observed_orcids":["https://orcid.org/0000-0002-5249-1521"]},"institutions":[{"id":"https://openalex.org/I4210149734","display_name":"Northwest Medical Specialties","ror":"https://ror.org/05hr4m393","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210149734"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sibel Blau","raw_affiliation_strings":["Northwest Medical Specialties, Puyallup, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northwest Medical Specialties, Puyallup, WA","institution_ids":["https://openalex.org/I4210149734"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110975690","display_name":"Michael A. Danso","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088931","display_name":"Virginia Oncology Associates","ror":"https://ror.org/009yyqs39","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210088931"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael A. Danso","raw_affiliation_strings":["Virginia Oncology Associates, Norfolk and Virginia Beach, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Oncology Associates, Norfolk and Virginia Beach, VA","institution_ids":["https://openalex.org/I4210088931"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029460219","display_name":"David Berz","orcid":"https://orcid.org/0000-0001-8368-4601","observed_orcids":["https://orcid.org/0000-0001-8368-4601"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Berz","raw_affiliation_strings":["Valkyrie Clinical Trials, Inc, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Valkyrie Clinical Trials, Inc, Los Angeles, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070006867","display_name":"Delia Constanza Guaqueta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210149825","display_name":"Memorial Regional Hospital","ror":"https://ror.org/04wpmby09","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210149825"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Delia Constanza Guaqueta","raw_affiliation_strings":["Memorial Regional Hospital, Hollywood, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Regional Hospital, Hollywood, FL","institution_ids":["https://openalex.org/I4210149825"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040276882","display_name":"John F. Schwerkoske","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165573","display_name":"Minnesota Oncology","ror":"https://ror.org/05vmsw483","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210165573"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John F. Schwerkoske","raw_affiliation_strings":["Minnesota Oncology Hematology P.A., Woodbury, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minnesota Oncology Hematology P.A., Woodbury, MN","institution_ids":["https://openalex.org/I4210165573"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071432873","display_name":"Joyce O\u2019Shaughnessy","orcid":"https://orcid.org/0000-0002-2955-5523","observed_orcids":["https://orcid.org/0000-0002-2955-5523","https://orcid.org/0000-0001-6764-2807"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joyce O'Shaughnessy","raw_affiliation_strings":["Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088119887","display_name":"Debra A. Patt","orcid":"https://orcid.org/0000-0001-5185-5170","observed_orcids":["https://orcid.org/0000-0001-5185-5170"]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Debra A. Patt","raw_affiliation_strings":["Texas Oncology, The US Oncology Network, Austin, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Texas Oncology, The US Oncology Network, Austin, TX","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034972183","display_name":"Aditya Bardia","orcid":"https://orcid.org/0000-0003-4885-1157","observed_orcids":["https://orcid.org/0000-0003-4885-1157"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I4390039293","display_name":"UCLA Jonsson Comprehensive Cancer Center","ror":"https://ror.org/0599cs764","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I4390039293"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aditya Bardia","raw_affiliation_strings":["Division of Hematology/Oncology, David Geffen School of Medicine at the University of California Los Angeles and Jonsson Comprehensive Cancer Center, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, David Geffen School of Medicine at the University of California Los Angeles and Jonsson Comprehensive Cancer Center, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I4390039293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062438676","display_name":"Kelly Elizabeth McCann","orcid":"https://orcid.org/0000-0001-8233-6242","observed_orcids":["https://orcid.org/0000-0001-8233-6242"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kelly Elizabeth McCann","raw_affiliation_strings":["Division of Hematology/Oncology, David Geffen School of Medicine at the University of California, Los Angeles and Beverly Hills Cancer Care, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, David Geffen School of Medicine at the University of California, Los Angeles and Beverly Hills Cancer Care, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044614018","display_name":"Andrew Paul Beelen","orcid":"https://orcid.org/0000-0001-9732-2089","observed_orcids":["https://orcid.org/0000-0001-9732-2089"]},"institutions":[{"id":"https://openalex.org/I4210144154","display_name":"G1 Therapeutics (United States)","ror":"https://ror.org/048389405","country_code":"US","type":"company","lineage":["https://openalex.org/I4210144154"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Paul Beelen","raw_affiliation_strings":["G1 Therapeutics, Inc., Research Triangle Park, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"G1 Therapeutics, Inc., Research Triangle Park, NC","institution_ids":["https://openalex.org/I4210144154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026532817","display_name":"Jingshan Zhang","orcid":"https://orcid.org/0000-0003-0409-1707","observed_orcids":["https://orcid.org/0000-0003-0409-1707"]},"institutions":[{"id":"https://openalex.org/I4210144154","display_name":"G1 Therapeutics (United States)","ror":"https://ror.org/048389405","country_code":"US","type":"company","lineage":["https://openalex.org/I4210144154"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jingshan Zhang","raw_affiliation_strings":["G1 Therapeutics, Inc., Research Triangle Park, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"G1 Therapeutics, Inc., Research Triangle Park, NC","institution_ids":["https://openalex.org/I4210144154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020208600","display_name":"John S. Yi","orcid":"https://orcid.org/0000-0001-7777-2437","observed_orcids":["https://orcid.org/0000-0001-7777-2437"]},"institutions":[{"id":"https://openalex.org/I4210144154","display_name":"G1 Therapeutics (United States)","ror":"https://ror.org/048389405","country_code":"US","type":"company","lineage":["https://openalex.org/I4210144154"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John S. Yi","raw_affiliation_strings":["G1 Therapeutics, Inc., Research Triangle Park, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"G1 Therapeutics, Inc., Research Triangle Park, NC","institution_ids":["https://openalex.org/I4210144154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068059897","display_name":"Sara Alsterlind Hurvitz","orcid":"https://orcid.org/0000-0001-7808-7191","observed_orcids":["https://orcid.org/0000-0001-7808-7191"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara A. Hurvitz","raw_affiliation_strings":["University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5104319650","display_name":"Mabel Alejandra Mardones","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210140702","display_name":"Rocky Mountain Cancer Centers","ror":"https://ror.org/03ynhs115","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210140702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mabel Alejandra Mardones","raw_affiliation_strings":["Rocky Mountain Cancer Centers/Sarah Cannon Research Institute, Denver, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rocky Mountain Cancer Centers/Sarah Cannon Research Institute, Denver, CO","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210140702"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":13,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"42","issue":"16_suppl","first_page":"1091","last_page":"1091"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.007499999832361937,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trilaciclib","display_name":"trilaciclib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/sacituzumab-govitecan","display_name":"sacituzumab govitecan","score":0.9990000128746033},{"id":"https://openalex.org/keywords/metastatic-triple-negative-breast-cancer","display_name":"metastatic triple-negative breast cancer","score":0.9879999756813049},{"id":"https://openalex.org/keywords/myeloprotection","display_name":"myeloprotection","score":0.9319999814033508},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.8180000185966492},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.8550000190734863},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7509999871253967},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.625},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.621999979019165},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.6740000247955322},{"id":"https://openalex.org/keywords/clinical-benefit-rate","display_name":"clinical benefit rate","score":0.7200000286102295},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7229999899864197},{"id":"https://openalex.org/keywords/t-cell-function","display_name":"T cell function","score":0.4259999990463257},{"id":"https://openalex.org/keywords/ascent-trial","display_name":"ASCENT trial","score":0.5849999785423279}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9071457386016846},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.808777928352356},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6264022588729858},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5974787473678589},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5031096339225769},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4924503266811371},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.40736424922943115}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2024.42.16_suppl.1091","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.1091","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.1091","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2024.42.16_suppl.1091","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1200/jco.2024.42.16_suppl.1091","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.1091","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.1091","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2024.42.16_suppl.1091","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320319266","display_name":"G1 Therapeutics","ror":"https://ror.org/048389405"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4399323701.pdf","grobid_xml":"https://content.openalex.org/works/W4399323701.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4376613532","https://openalex.org/W2977663305","https://openalex.org/W4396588106","https://openalex.org/W3167666502","https://openalex.org/W2977211443","https://openalex.org/W4411286243","https://openalex.org/W4414913370","https://openalex.org/W4296643044","https://openalex.org/W4200310043","https://openalex.org/W3129749107"],"abstract_inverted_index":{"1091":[0],"Background:":[1],"Trilaciclib,":[2],"a":[3,19,39,219],"reversible":[4],"cyclin-dependent":[5],"kinase":[6],"4/6":[7],"inhibitor,":[8],"protects":[9],"hematopoietic":[10],"stem":[11],"and":[12,34,77,100,129,159,197,199,217,253,301,309],"progenitor":[13],"cells":[14],"during":[15],"chemotherapy":[16,30,56],"(myeloprotection).":[17],"In":[18,38],"phase":[20,40,91],"2":[21,92,114],"trial":[22,42,94,358],"in":[23,107,120,233],"mTNBC":[24,108],"(NCT02978716),":[25],"administering":[26],"trilaciclib":[27,103,148,283,294,329],"prior":[28,104,115,151,284,295,330],"to":[29,97,105,152,285,296,331],"enhanced":[31],"T-cell":[32],"activity":[33],"modulated":[35],"antitumor":[36,194],"immunity.":[37],"3":[41],"(ASCENT;":[43],"NCT02574455),":[44],"the":[45,121,234,246,254,299],"antibody\u2013drug":[46],"conjugate":[47],"SG":[48,106,153,286,297,317,332,338],"significantly":[49],"extended":[50],"overall":[51,238],"survival":[52,266],"(OS)":[53],"versus":[54],"single-agent":[55],"(12.1":[57],"vs":[58,70,75,82,87],"6.7":[59],"months)":[60],"but":[61],"was":[62,95,227,243,250,259,267],"associated":[63],"with":[64,312,334],"increased":[65],"neutropenia":[66,308],"(any":[67,79],"grade,":[68,80],"63%":[69],"43%;":[71],"grade":[72,84],"3/4,":[73,85],"51%":[74],"33%)":[76],"diarrhea":[78],"59%":[81],"12%;":[83],"10%":[86],"<":[88],"1%).":[89],"This":[90],"single-arm":[93],"designed":[96],"assess":[98],"safety":[99,198],"efficacy":[101],"of":[102,161,203,257,303,316],"(NCT05113966).":[109],"Methods:":[110],"Eligible":[111],"patients":[112,209,281,327],"(\u2265":[113],"systemic":[116],"therapies":[117],"[\u2265":[118],"1":[119,158],"metastatic":[122],"setting];":[123],"measurable":[124],"disease;":[125],"confirmed":[126,237],"hormone":[127],"receptor-":[128],"human":[130],"epidermal":[131],"growth":[132],"factor":[133],"receptor":[134],"2-negative":[135],"status;":[136],"Eastern":[137],"Cooperative":[138],"Oncology":[139],"Group":[140],"performance":[141],"status":[142],"0":[143],"or":[144,168,188],"1)":[145],"received":[146],"intravenous":[147],"240":[149],"mg/m2":[150],"10":[154],"mg/kg":[155],"on":[156],"days":[157],"8":[160],"each":[162],"21-day":[163],"cycle":[164],"until":[165,185],"disease":[166,186],"progression":[167,187],"toxicity.":[169],"Tumor":[170],"assessments":[171],"occurred":[172],"at":[173],"screening,":[174],"every":[175,182],"6":[176,221],"weeks":[177,184],"through":[178],"week":[179],"26,":[180],"then":[181],"9":[183],"subsequent":[189],"anticancer":[190],"therapy.":[191],"Endpoints":[192],"included":[193],"efficacy,":[195],"myeloprotection,":[196],"tolerability.":[200],"Results:":[201],"As":[202],"January":[204],"2,":[205],"2024,":[206],"30":[207],"female":[208],"had":[210],"been":[211],"enrolled":[212],"(median":[213],"age,":[214],"56":[215],"years)":[216],"completed":[218],"median":[220,255,278],"(range,":[222],"2\u201329)":[223],"cycles.":[224],"Median":[225,264],"follow-up":[226],"11.2":[228],"months.":[229,263,270,291],"Safety":[230],"is":[231,287],"summarized":[232],"Table.":[235],"The":[236],"response":[239,258],"rate":[240,249,300],"(95%":[241],"CI)":[242],"23.3%":[244],"(9.9\u201342.3),":[245],"clinical":[247],"benefit":[248],"46.7%":[251],"(28.3\u201365.7),":[252],"duration":[256],"9.1":[260],"(4.0\u2013not":[261],"estimable)":[262,290],"progression-free":[265],"4.1":[268],"(2.2\u20137.3)":[269],"OS":[271,279,324,352],"data":[272,320,336,353],"are":[273],"not":[274],"yet":[275],"mature;":[276],"currently,":[277],"among":[280,326],"receiving":[282,328],"17.9":[288],"(9.9\u2013not":[289],"Conclusions:":[292],"Adding":[293],"reduces":[298],"severity":[302],"multiple":[304],"adverse":[305],"events,":[306],"notably":[307],"diarrhea,":[310],"compared":[311,333],"results":[313,347],"from":[314,348],"trials":[315],"alone.":[318],"Preliminary":[319],"suggest":[321],"clinically":[322],"meaningful":[323],"outcomes":[325],"historical":[335],"for":[337],"alone;":[339],"however,":[340],"caution":[341],"should":[342],"be":[343,355],"exercised":[344],"when":[345],"interpreting":[346],"cross-trial":[349],"comparisons.":[350],"Mature":[351],"will":[354],"presented.":[356],"Clinical":[357],"information:":[359],"NCT05113966":[360],".":[361],"[Table:":[362],"see":[363],"text]":[364]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2024-06-05T00:00:00"}